-
1
-
-
77949822338
-
NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas
-
Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
-
(2010)
J Natl Compr Canc Netw.
, vol.8
, Issue.3
, pp. 288-334
-
-
Zelenetz, A.D.1
Abramson, J.S.2
Advani, R.H.3
-
3
-
-
77957200763
-
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte
-
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
-
(2010)
Blood.
, vol.116
, Issue.12
, pp. 2040-2045
-
-
Coiffier, B.1
Thieblemont, C.2
Van Den Neste, E.3
-
4
-
-
34548221347
-
Mechanisms of killing by anti-CD20 monoclonal antibodies
-
Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16): 3823-3837.
-
(2007)
Mol Immunol.
, vol.44
, Issue.16
, pp. 3823-3837
-
-
Glennie, M.J.1
French, R.R.2
Cragg, M.S.3
Taylor, R.P.4
-
5
-
-
0033855660
-
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
-
Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135-3143.
-
(2000)
J Clin Oncol.
, vol.18
, Issue.17
, pp. 3135-3143
-
-
Davis, T.A.1
Grillo-López, A.J.2
White, C.A.3
-
6
-
-
57349104217
-
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome A GEL/TAMO study
-
Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93(12):1829-1836.
-
(2008)
Haematologica.
, vol.93
, Issue.12
, pp. 1829-1836
-
-
Martín, A.1
Conde, E.2
Arnan, M.3
-
7
-
-
33646879148
-
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study
-
Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17 Suppl 4:iv31-iv32.
-
(2006)
Ann Oncol.
, vol.17
, Issue.SUPPL. 4
-
-
Hagberg, H.1
Gisselbrecht, C.2
-
9
-
-
77958009878
-
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
-
Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia. 2010;24(10):1760-1768.
-
(2010)
Leukemia.
, vol.24
, Issue.10
, pp. 1760-1768
-
-
Shimizu, R.1
Kikuchi, J.2
Wada, T.3
Ozawa, K.4
Kano, Y.5
Furukawa, Y.6
-
10
-
-
0032761285
-
Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
-
Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3776-3785.
-
(1999)
J Clin Oncol.
, vol.17
, Issue.12
, pp. 3776-3785
-
-
Moskowitz, C.H.1
Bertino, J.R.2
Glassman, J.R.3
-
11
-
-
1842829171
-
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
-
Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684-3688.
-
(2004)
Blood.
, vol.103
, Issue.10
, pp. 3684-3688
-
-
Kewalramani, T.1
Zelenetz, A.D.2
Nimer, S.D.3
-
12
-
-
0034649696
-
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
-
Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-1757.
-
(2000)
N Engl J Med.
, vol.343
, Issue.24
, pp. 1750-1757
-
-
Rai, K.R.1
Peterson, B.L.2
Appelbaum, F.R.3
-
13
-
-
80053085439
-
Progress in the treatment of chronic lymphocytic leukemia: Results of the German CLL8 trial
-
Molica S. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial. Expert Rev Anticancer Ther. 2011; 11(9):1333-1340.
-
(2011)
Expert Rev Anticancer Ther.
, vol.11
, Issue.9
, pp. 1333-1340
-
-
Molica, S.1
-
14
-
-
34447530283
-
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial
-
Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230-239.
-
(2007)
Lancet.
, vol.370
, Issue.9583
, pp. 230-239
-
-
Catovsky, D.1
Richards, S.2
Matutes, E.3
-
15
-
-
0034727833
-
Genomic aberrations and survival in chronic lymphocytic leukemia
-
Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916.
-
(2000)
N Engl J Med.
, vol.343
, Issue.26
, pp. 1910-1916
-
-
Dohner, H.1
Stilgenbauer, S.2
Benner, A.3
-
16
-
-
33749545033
-
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
-
van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-3301.
-
(2006)
Blood.
, vol.108
, Issue.10
, pp. 3295-3301
-
-
van Oers, M.H.1
Klasa, R.2
Marcus, R.E.3
-
17
-
-
0036256650
-
Treatment of relapsed aggressive lymphomas: Regimens with and without high-dose therapy and stem cell rescue
-
Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002;49 Suppl 1:S13-S20.
-
(2002)
Cancer Chemother Pharmacol.
, vol.49
, Issue.SUPPL. 1
-
-
Hagemeister, F.B.1
-
18
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
-
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
-
(1995)
N Engl J Med.
, vol.333
, Issue.23
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
-
19
-
-
0038702514
-
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
-
Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31(8):667-678.
-
(2003)
Bone Marrow Transplant.
, vol.31
, Issue.8
, pp. 667-678
-
-
Peniket, A.J.1
Ruiz de Elvira, M.C.2
Taghipour, G.3
-
20
-
-
34248193253
-
Immune surveillance of tumors
-
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-1146.
-
(2007)
J Clin Invest.
, vol.117
, Issue.5
, pp. 1137-1146
-
-
Swann, J.B.1
Smyth, M.J.2
-
21
-
-
46449101522
-
Hematopoietic cell transplantation for non-Hodgkin's lymphoma: Yesterday, today, and tomorrow
-
Appelbaum FR. Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. J Clin Oncol. 2008;26(18): 2927-2929.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.18
, pp. 2927-2929
-
-
Appelbaum, F.R.1
-
22
-
-
84859410688
-
The treatment of relapsed refractory chronic lymphocytic leukemia
-
Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011: 110-118.
-
(2011)
Hematology Am Soc Hematol Educ Program.
, vol.2011
, pp. 110-118
-
-
Brown, J.R.1
-
24
-
-
84867236304
-
Novel CD20 monoclonal antibodies for lymphoma therapy
-
Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64.
-
(2012)
J Hematol Oncol.
, vol.5
, pp. 64
-
-
Cang, S.1
Mukhi, N.2
Wang, K.3
Liu, D.4
-
25
-
-
77955300283
-
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
-
Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28(21): 3525-3530.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.21
, pp. 3525-3530
-
-
Cheson, B.D.1
-
26
-
-
4444343395
-
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
-
Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800.
-
(2004)
Blood.
, vol.104
, Issue.6
, pp. 1793-1800
-
-
Teeling, J.L.1
French, R.R.2
Cragg, M.S.3
-
27
-
-
84864748652
-
Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
-
Gupta IV, Jewell RC. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci. 2012;1263:43-56.
-
(2012)
Ann N Y Acad Sci.
, vol.1263
, pp. 43-56
-
-
Gupta, I.V.1
Jewell, R.C.2
-
28
-
-
38949185742
-
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study
-
Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094-1100.
-
(2008)
Blood.
, vol.111
, Issue.3
, pp. 1094-1100
-
-
Coiffier, B.1
Lepretre, S.2
Pedersen, L.M.3
-
29
-
-
77950502126
-
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
-
Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.10
, pp. 1749-1755
-
-
Wierda, W.G.1
Kipps, T.J.2
Mayer, J.3
-
30
-
-
79959190996
-
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
-
Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117(24):6450-6458.
-
(2011)
Blood.
, vol.117
, Issue.24
, pp. 6450-6458
-
-
Wierda, W.G.1
Kipps, T.J.2
Durig, J.3
-
31
-
-
84860344201
-
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: Results from a multicenter study
-
Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698-3704.
-
(2012)
Blood.
, vol.119
, Issue.16
, pp. 3698-3704
-
-
Czuczman, M.S.1
Fayad, L.2
Delwail, V.3
-
32
-
-
84860006054
-
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
-
Czuczman MS, Hess G, Gadeberg OV, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157(4):438-445.
-
(2012)
Br J Haematol.
, vol.157
, Issue.4
, pp. 438-445
-
-
Czuczman, M.S.1
Hess, G.2
Gadeberg, O.V.3
-
33
-
-
77955175014
-
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
-
Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010;21(9): 1870-1876.
-
(2010)
Ann Oncol.
, vol.21
, Issue.9
, pp. 1870-1876
-
-
Morschhauser, F.1
Marlton, P.2
Vitolo, U.3
-
34
-
-
77951829072
-
Veltuzumab (humanized anti-CD20 monoclonal antibody): Characterization, current clinical results, and future prospects
-
Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010;51(5):747-755.
-
(2010)
Leuk Lymphoma.
, vol.51
, Issue.5
, pp. 747-755
-
-
Goldenberg, D.M.1
Morschhauser, F.2
Wegener, W.A.3
-
35
-
-
70249106098
-
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results
-
Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27(20):3346-3353.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.20
, pp. 3346-3353
-
-
Morschhauser, F.1
Leonard, J.P.2
Fayad, L.3
-
37
-
-
0036182540
-
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
-
Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol. 2002;29(1 Suppl 2):81-86.
-
(2002)
Semin Oncol.
, vol.29
, Issue.1 SUPPL. 2
, pp. 81-86
-
-
Leonard, J.P.1
Link, B.K.2
-
38
-
-
33748471355
-
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
-
Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(24):3880-3886.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.24
, pp. 3880-3886
-
-
Strauss, S.J.1
Morschhauser, F.2
Rech, J.3
-
39
-
-
1842735276
-
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
-
Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol. 2004;111(1):28-37.
-
(2004)
Clin Immunol.
, vol.111
, Issue.1
, pp. 28-37
-
-
Gottlieb, A.B.1
Kang, S.2
Linden, K.G.3
-
40
-
-
0031831856
-
Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma
-
Vyth-Dreese FA, Boot H, Dellemijn TA, et al. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology. 1998;94(4):580-586.
-
(1998)
Immunology.
, vol.94
, Issue.4
, pp. 580-586
-
-
Vyth-Dreese, F.A.1
Boot, H.2
Dellemijn, T.A.3
-
41
-
-
22344436992
-
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
-
Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005;23(19):4390-4398.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.19
, pp. 4390-4398
-
-
Czuczman, M.S.1
Thall, A.2
Witzig, T.E.3
-
42
-
-
84865564961
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
-
Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2012;23(9):2356-2362.
-
(2012)
Ann Oncol.
, vol.23
, Issue.9
, pp. 2356-2362
-
-
Czuczman, M.S.1
Leonard, J.P.2
Jung, S.3
-
43
-
-
12444272236
-
Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome
-
Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625-3634.
-
(2003)
Clin Cancer Res.
, vol.9
, Issue.10 PART 1
, pp. 3625-3634
-
-
Ishida, T.1
Utsunomiya, A.2
Iida, S.3
-
44
-
-
77951916883
-
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma
-
Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591-1598.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.9
, pp. 1591-1598
-
-
Yamamoto, K.1
Utsunomiya, A.2
Tobinai, K.3
-
45
-
-
84863393084
-
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study
-
Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837-842.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.8
, pp. 837-842
-
-
Ishida, T.1
Joh, T.2
Uike, N.3
-
46
-
-
77951648118
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase I study
-
Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.12
, pp. 2085-2093
-
-
Advani, A.1
Coiffier, B.2
Czuczman, M.S.3
-
47
-
-
67650873888
-
Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase 1/2 study
-
Fayad L, Patel H, Verhoef G, et al. Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. ASH Annu Meet Abstr. 2008;112(11):266.
-
(2008)
ASH Annu Meet Abstr.
, vol.112
, Issue.11
, pp. 266
-
-
Fayad, L.1
Patel, H.2
Verhoef, G.3
-
48
-
-
0030777876
-
Reed-Sternberg cells and the TNF family of receptors/ligands
-
Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma. 1997;27(3-4):195-205.
-
(1997)
Leuk Lymphoma.
, vol.27
, Issue.3-4
, pp. 195-205
-
-
Clodi, K.1
Younes, A.2
-
49
-
-
67649908324
-
A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
-
Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-179.
-
(2009)
Br J Haematol.
, vol.146
, Issue.2
, pp. 171-179
-
-
Forero-Torres, A.1
Leonard, J.P.2
Younes, A.3
-
50
-
-
77958490178
-
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism
-
Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21(11): 2246-2254.
-
(2010)
Ann Oncol.
, vol.21
, Issue.11
, pp. 2246-2254
-
-
Blum, K.A.1
Jung, S.H.2
Johnson, J.L.3
-
51
-
-
84878864024
-
Brentuximab vedotin: A review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure
-
Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs. 2013;73(4):371-381.
-
(2013)
Drugs.
, vol.73
, Issue.4
, pp. 371-381
-
-
Garnock-Jones, K.P.1
-
52
-
-
84863678237
-
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
-
Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.18
, pp. 2190-2196
-
-
Pro, B.1
Advani, R.2
Brice, P.3
-
53
-
-
84867857964
-
Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma
-
Viardot A, Goebeler M, Nopponey R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. ASH Annu Meet Abstr. 2011;188:1637.
-
(2011)
ASH Annu Meet Abstr.
, vol.188
, pp. 1637
-
-
Viardot, A.1
Goebeler, M.2
Nopponey, R.3
-
54
-
-
0035478728
-
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
-
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19(19):3918-3928.
-
(2001)
J Clin Oncol.
, vol.19
, Issue.19
, pp. 3918-3928
-
-
Kaminski, M.S.1
Zelenetz, A.D.2
Press, O.W.3
-
55
-
-
32944476224
-
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
-
Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(30):7565-7573.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.30
, pp. 7565-7573
-
-
Fisher, R.I.1
Kaminski, M.S.2
Wahl, R.L.3
-
56
-
-
14144249536
-
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab
-
Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23(4):712-719.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.4
, pp. 712-719
-
-
Horning, S.J.1
Younes, A.2
Jain, V.3
-
57
-
-
0036682214
-
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
-
Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(15):3262-3269.
-
(2002)
J Clin Oncol.
, vol.20
, Issue.15
, pp. 3262-3269
-
-
Witzig, T.E.1
Flinn, I.W.2
Gordon, L.I.3
-
58
-
-
2942595713
-
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study
-
Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103(12): 4429-4431.
-
(2004)
Blood.
, vol.103
, Issue.12
, pp. 4429-4431
-
-
Gordon, L.I.1
Molina, A.2
Witzig, T.3
-
59
-
-
84873397196
-
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
-
Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314-320.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.3
, pp. 314-320
-
-
Press, O.W.1
Unger, J.M.2
Rimsza, L.M.3
-
60
-
-
0038175332
-
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma
-
Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(7):1263-1270.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.7
, pp. 1263-1270
-
-
Witzig, T.E.1
White, C.A.2
Gordon, L.I.3
-
61
-
-
74849131675
-
Radioimmunotherapy of lymphoma: Bexxar and Zevalin
-
Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40(2):122-135.
-
(2010)
Semin Nucl Med.
, vol.40
, Issue.2
, pp. 122-135
-
-
Goldsmith, S.J.1
-
62
-
-
20444411092
-
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
-
Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105(12):4576-4582.
-
(2005)
Blood.
, vol.105
, Issue.12
, pp. 4576-4582
-
-
Bennett, J.M.1
Kaminski, M.S.2
Leonard, J.P.3
-
63
-
-
34948845600
-
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
-
Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25(27):4285-4292.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.27
, pp. 4285-4292
-
-
Czuczman, M.S.1
Emmanouilides, C.2
Darif, M.3
-
64
-
-
84874650275
-
Development of PI3K inhibitors: Lessons learned from early clinical trials
-
Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
-
(2013)
Nat Rev Clin Oncol.
, vol.10
, Issue.3
, pp. 143-153
-
-
Rodon, J.1
Dienstmann, R.2
Serra, V.3
Tabernero, J.4
-
65
-
-
80755139573
-
Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: Results, biology, and development strategies
-
Schatz JH. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011;13(5):398-406.
-
(2011)
Curr Oncol Rep.
, vol.13
, Issue.5
, pp. 398-406
-
-
Schatz, J.H.1
-
66
-
-
67749122122
-
Targeting PI3K signalling in cancer: Opportunities, challenges and limitations
-
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
-
(2009)
Nat Rev Cancer.
, vol.9
, Issue.8
, pp. 550-562
-
-
Engelman, J.A.1
-
67
-
-
77957201023
-
Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
-
Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088.
-
(2010)
Blood.
, vol.116
, Issue.12
, pp. 2078-2088
-
-
Herman, S.E.1
Gordon, A.L.2
Wagner, A.J.3
-
68
-
-
79958784935
-
Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with relapsed or refractory non-Hodgkin lymphoma
-
Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Ann Meet Abstr. 2010;166:1777.
-
(2010)
ASH Ann Meet Abstr.
, vol.166
, pp. 1777
-
-
Kahl, B.1
Byrd, J.C.2
Flinn, I.W.3
-
69
-
-
79953655788
-
CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia
-
Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Ann Meet Abstr. 2010;116:55.
-
(2010)
ASH Ann Meet Abstr.
, vol.116
, pp. 55
-
-
Furman, R.R.1
Byrd, J.C.2
Brown, J.R.3
-
70
-
-
84875777300
-
Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a phase I study
-
Coutre SE, Leonard JP, Furman RR, et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study. ASH Ann Meet Abstr. 2012;120:191.
-
(2012)
ASH Ann Meet Abstr.
, vol.120
, pp. 191
-
-
Coutre, S.E.1
Leonard, J.P.2
Furman, R.R.3
-
71
-
-
84871406720
-
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)
-
Furman RR, Barrientos JC, Sharman JP, et al. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2012;30 Suppl:6518.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL.
, pp. 6518
-
-
Furman, R.R.1
Barrientos, J.C.2
Sharman, J.P.3
-
72
-
-
84870413230
-
A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia
-
Robak P, Robak T. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Curr Med Chem. 2012;19(31): 5294-5318.
-
(2012)
Curr Med Chem.
, vol.19
, Issue.31
, pp. 5294-5318
-
-
Robak, P.1
Robak, T.2
-
73
-
-
84859948881
-
Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: Mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
-
Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012;8(5):623-633.
-
(2012)
Expert Opin Drug Metab Toxicol.
, vol.8
, Issue.5
, pp. 623-633
-
-
Richardson, P.G.1
Eng, C.2
Kolesar, J.3
Hideshima, T.4
Anderson, K.C.5
-
74
-
-
84884231758
-
Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: Final results of a phase II trial
-
Guidetti A, Viviani S, Marchiano A, et al. Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: final results of a phase II trial. ASH Annu Meet Abstr. 2012;120:3679.
-
(2012)
ASH Annu Meet Abstr.
, vol.120
, pp. 3679
-
-
Guidetti, A.1
Viviani, S.2
Marchiano, A.3
-
75
-
-
67650744339
-
Primary B cell immunodeficiencies: Comparisons and contrasts
-
Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
-
(2009)
Annu Rev Immunol.
, vol.27
, pp. 199-227
-
-
Conley, M.E.1
Dobbs, A.K.2
Farmer, D.M.3
-
76
-
-
73849145729
-
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
-
Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277): 88-92.
-
(2010)
Nature.
, vol.463
, Issue.7277
, pp. 88-92
-
-
Davis, R.E.1
Ngo, V.N.2
Lenz, G.3
-
77
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
-
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.1
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
-
78
-
-
84861345119
-
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study
-
O'Brien S, Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. ASH Annu Meet Abstr. 2011;118:983.
-
(2011)
ASH Annu Meet Abstr.
, vol.118
, pp. 983
-
-
O'Brien, S.1
Burger, J.A.2
Blum, K.A.3
-
79
-
-
84867840656
-
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study
-
Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. J Clin Oncol. 2012;30 Suppl:6507.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL.
, pp. 6507
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
-
80
-
-
84867843137
-
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (Pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study
-
O'Brien SM, Barrientos JC, Flinn IW, et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (Pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II study J Clin Oncol. 2012;30 Suppl:6515.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL.
, pp. 6515
-
-
O'Brien, S.M.1
Barrientos, J.C.2
Flinn, I.W.3
-
81
-
-
84867853067
-
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases
-
Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol. 2012;30 Suppl:6508.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL.
, pp. 6508
-
-
Jaglowski, S.M.1
Jones, J.A.2
Flynn, J.M.3
-
82
-
-
84871740442
-
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials
-
Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013;8(1): 1-6.
-
(2013)
Curr Hematol Malig Rep.
, vol.8
, Issue.1
, pp. 1-6
-
-
Brown, J.R.1
-
83
-
-
84867889132
-
Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)
-
Brown JR, Sharman JP, Harb WA, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin Oncol. 2012;30 Suppl:8032.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL.
, pp. 8032
-
-
Brown, J.R.1
Sharman, J.P.2
Harb, W.A.3
-
84
-
-
0035886032
-
Rapamycin: Clinical results and future opportunities
-
Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72(7):1181-1193.
-
(2001)
Transplantation.
, vol.72
, Issue.7
, pp. 1181-1193
-
-
Kahan, B.D.1
Camardo, J.S.2
-
85
-
-
0034901515
-
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
-
Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001;7(6):1758-1764.
-
(2001)
Clin Cancer Res.
, vol.7
, Issue.6
, pp. 1758-1764
-
-
Dudkin, L.1
Dilling, M.B.2
Cheshire, P.J.3
-
86
-
-
27144455334
-
Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
-
Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica. 2005;90(10):1433-1434.
-
(2005)
Haematologica.
, vol.90
, Issue.10
, pp. 1433-1434
-
-
Hipp, S.1
Ringshausen, I.2
Oelsner, M.3
Bogner, C.4
Peschel, C.5
Decker, T.6
-
87
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822-3829.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.23
, pp. 3822-3829
-
-
Hess, G.1
Herbrecht, R.2
Romaguera, J.3
-
88
-
-
78149239933
-
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
-
Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740-4746.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.31
, pp. 4740-4746
-
-
Smith, S.M.1
van Besien, K.2
Karrison, T.3
-
89
-
-
79751526328
-
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
-
Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341-347.
-
(2011)
Leukemia.
, vol.25
, Issue.2
, pp. 341-347
-
-
Witzig, T.E.1
Reeder, C.B.2
LaPlant, B.R.3
-
90
-
-
77951450222
-
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
-
Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010;116(9):2201-2207.
-
(2010)
Cancer.
, vol.116
, Issue.9
, pp. 2201-2207
-
-
Zent, C.S.1
LaPlant, B.R.2
Johnston, P.B.3
-
91
-
-
84870561467
-
B-cell receptor pathobiology and targeting in NHL
-
Macias-Perez IM, Flinn IW. B-cell receptor pathobiology and targeting in NHL. Curr Oncol Rep. 2012;14(5):411-418.
-
(2012)
Curr Oncol Rep.
, vol.14
, Issue.5
, pp. 411-418
-
-
Macias-Perez, I.M.1
Flinn, I.W.2
-
92
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13): 2578-2585.
-
(2010)
Blood.
, vol.115
, Issue.13
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
-
93
-
-
84884540287
-
-
AstraZeneca. Bethesda, MD: US National Library of Medicine; [updated June 4, 2013]. Available from: NLM identifier: NCT01499303. Accessed June 17, 2013
-
AstraZeneca. Study to learn if 200 mg test drug (fostamatinib) helps people with large B-cell lymphoma, a type of blood cancer. Bethesda, MD: US National Library of Medicine; 2011 [updated June 4, 2013]. Available from: http://clinicaltrials.gov/show/NCT01499303. NLM identifier: NCT01499303. Accessed June 17, 2013.
-
(2011)
Study to learn if 200 mg test drug (fostamatinib) helps people with large B-cell lymphoma, a type of blood cancer
-
-
-
94
-
-
84884568094
-
A randomised double blind phase II trial to evaluate the efficacy of two doses of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
NLM identifier: NCT01499303
-
AstraZeneca. A randomised double blind phase II trial to evaluate the efficacy of two doses of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NLM identifier: NCT01499303.
-
AstraZeneca
-
-
-
95
-
-
0030985194
-
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
-
Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90(1):244-251.
-
(1997)
Blood.
, vol.90
, Issue.1
, pp. 244-251
-
-
Gascoyne, R.D.1
Adomat, S.A.2
Krajewski, S.3
-
96
-
-
54049111866
-
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
-
Stolz C, Hess G, Hahnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008;112(8):3312-3321.
-
(2008)
Blood.
, vol.112
, Issue.8
, pp. 3312-3321
-
-
Stolz, C.1
Hess, G.2
Hahnel, P.S.3
-
97
-
-
34248584099
-
Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
-
Wobser M, Voigt H, Eggert AO, et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer. 2007;96(10): 1540-1543.
-
(2007)
Br J Cancer.
, vol.96
, Issue.10
, pp. 1540-1543
-
-
Wobser, M.1
Voigt, H.2
Eggert, A.O.3
-
98
-
-
0034015672
-
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
-
Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000;18(9): 1812-1823.
-
(2000)
J Clin Oncol.
, vol.18
, Issue.9
, pp. 1812-1823
-
-
Waters, J.S.1
Webb, A.2
Cunningham, D.3
-
99
-
-
54049145194
-
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
-
Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143(3):355-360.
-
(2008)
Br J Haematol.
, vol.143
, Issue.3
, pp. 355-360
-
-
Pro, B.1
Leber, B.2
Smith, M.3
-
100
-
-
70449723145
-
5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen
-
O'Brien S, Moore JO, Boyd TE, et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009;27(31):5208-5212.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.31
, pp. 5208-5212
-
-
O'Brien, S.1
Moore, J.O.2
Boyd, T.E.3
-
101
-
-
78649630259
-
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
-
Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159.
-
(2010)
Lancet Oncol.
, vol.11
, Issue.12
, pp. 1149-1159
-
-
Wilson, W.H.1
O'Connor, O.A.2
Czuczman, M.S.3
-
102
-
-
84859777882
-
Navitoclax (ABT-263) plus rituximab: Interim results of a phase 1 study in patients with CD20-positive lymphoid malignancies
-
Kahl B, Roberts AW, Seymour JF, et al. Navitoclax (ABT-263) plus rituximab: interim results of a phase 1 study in patients with CD20-positive lymphoid malignancies. ASH Annu Meet Abstr. 2010;116:3943.
-
(2010)
ASH Annu Meet Abstr.
, vol.116
, pp. 3943
-
-
Kahl, B.1
Roberts, A.W.2
Seymour, J.F.3
-
103
-
-
84874688338
-
Histone deacetylases as targets for treatment of multiple diseases
-
Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond). 2013;124(11):651-662.
-
(2013)
Clin Sci (Lond).
, vol.124
, Issue.11
, pp. 651-662
-
-
Tang, J.1
Yan, H.2
Zhuang, S.3
-
104
-
-
79952773321
-
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
-
Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198-1203.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.9
, pp. 1198-1203
-
-
Kirschbaum, M.1
Frankel, P.2
Popplewell, L.3
-
105
-
-
84875813981
-
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
-
Budde LE, Zhang MM, Shustov AR, et al. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol. 2013;161(2):183-191.
-
(2013)
Br J Haematol.
, vol.161
, Issue.2
, pp. 183-191
-
-
Budde, L.E.1
Zhang, M.M.2
Shustov, A.R.3
-
106
-
-
77957965500
-
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
-
Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.27
, pp. 4184-4190
-
-
Gisselbrecht, C.1
Glass, B.2
Mounier, N.3
-
107
-
-
79952977561
-
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
-
Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827-5834.
-
(2011)
Blood.
, vol.117
, Issue.22
, pp. 5827-5834
-
-
Piekarz, R.L.1
Frye, R.2
Prince, H.M.3
-
108
-
-
0038521374
-
Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials
-
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
-
(2003)
Cancer.
, vol.97
, Issue.11
, pp. 2869-2879
-
-
Swain, S.M.1
Whaley, F.S.2
Ewer, M.S.3
-
109
-
-
84872719512
-
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients
-
Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013;344(2): 467-478.
-
(2013)
J Pharmacol Exp Ther.
, vol.344
, Issue.2
, pp. 467-478
-
-
Salvatorelli, E.1
Menna, P.2
Paz, O.G.3
-
110
-
-
2642566088
-
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
-
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229.
-
(2004)
Pharmacol Rev.
, vol.56
, Issue.2
, pp. 185-229
-
-
Minotti, G.1
Menna, P.2
Salvatorelli, E.3
Cairo, G.4
Gianni, L.5
-
111
-
-
34248642248
-
Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone
-
Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007;25(3):187-195.
-
(2007)
Invest New Drugs.
, vol.25
, Issue.3
, pp. 187-195
-
-
Cavalletti, E.1
Crippa, L.2
Mainardi, P.3
-
112
-
-
0034988022
-
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma
-
Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol. 2001;12(5):661-667.
-
(2001)
Ann Oncol.
, vol.12
, Issue.5
, pp. 661-667
-
-
Borchmann, P.1
Schnell, R.2
Knippertz, R.3
-
113
-
-
84863113681
-
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomised trial
-
Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7):696-706.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.7
, pp. 696-706
-
-
Pettengell, R.1
Coiffier, B.2
Narayanan, G.3
-
114
-
-
33645538920
-
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas
-
Paoluzzi L, O'Connor OA. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs. 2006;20(1):13-23.
-
(2006)
BioDrugs.
, vol.20
, Issue.1
, pp. 13-23
-
-
Paoluzzi, L.1
O'Connor, O.A.2
-
115
-
-
79953077610
-
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
-
Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117(10):2807-2812.
-
(2011)
Blood.
, vol.117
, Issue.10
, pp. 2807-2812
-
-
Friedberg, J.W.1
Vose, J.M.2
Kelly, J.L.3
-
116
-
-
70349300630
-
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)
-
Ribrag V, Gisselbrecht C, Haioun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009;115(19):4540-4546.
-
(2009)
Cancer.
, vol.115
, Issue.19
, pp. 4540-4546
-
-
Ribrag, V.1
Gisselbrecht, C.2
Haioun, C.3
-
117
-
-
77349086121
-
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma
-
de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023-5030.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.30
, pp. 5023-5030
-
-
de Vos, S.1
Goy, A.2
Dakhil, S.R.3
-
118
-
-
77958541490
-
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
-
Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol. 2010;151(4): 346-353.
-
(2010)
Br J Haematol.
, vol.151
, Issue.4
, pp. 346-353
-
-
Agathocleous, A.1
Rohatiner, A.2
Rule, S.3
-
119
-
-
33750625445
-
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
-
Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-4874.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.30
, pp. 4867-4874
-
-
Fisher, R.I.1
Bernstein, S.H.2
Kahl, B.S.3
-
120
-
-
84889095552
-
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study
-
Epub October 29
-
Zinzani PL, Pellegrini C, Merla E, et al. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Hematol Oncol. Epub October 29, 2012.
-
(2012)
Hematol Oncol.
-
-
Zinzani, P.L.1
Pellegrini, C.2
Merla, E.3
-
121
-
-
79960892918
-
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: A randomised phase 3 trial
-
Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12(8):773-784.
-
(2011)
Lancet Oncol.
, vol.12
, Issue.8
, pp. 773-784
-
-
Coiffier, B.1
Osmanov, E.A.2
Hong, X.3
-
122
-
-
84864929837
-
Lenalidomide in diffuse large B-cell lymphomas
-
Chiappella A, Vitolo U. Lenalidomide in diffuse large B-cell lymphomas. Adv Hematol. 2012;2012:498342.
-
(2012)
Adv Hematol.
, vol.2012
, pp. 498342
-
-
Chiappella, A.1
Vitolo, U.2
-
123
-
-
54449095901
-
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
-
Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(30):4952-4957.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.30
, pp. 4952-4957
-
-
Wiernik, P.H.1
Lossos, I.S.2
Tuscano, J.M.3
-
124
-
-
79959722615
-
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
-
Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-1627.
-
(2011)
Ann Oncol.
, vol.22
, Issue.7
, pp. 1622-1627
-
-
Witzig, T.E.1
Vose, J.M.2
Zinzani, P.L.3
-
125
-
-
84857654592
-
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial
-
Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11(6):462-466.
-
(2011)
Clin Lymphoma Myeloma Leuk.
, vol.11
, Issue.6
, pp. 462-466
-
-
Zinzani, P.L.1
Pellegrini, C.2
Gandolfi, L.3
-
126
-
-
84863107308
-
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial
-
Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13(7):716-723.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.7
, pp. 716-723
-
-
Wang, M.1
Fayad, L.2
Wagner-Bartak, N.3
-
127
-
-
84876009736
-
Rituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): Results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL)
-
Presented at:; December 8-11, Atlanta, GA, USA
-
Chiappella A, Franceschetti S, Castellino A, Carella AM, et al. Rituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL). Presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA, USA.
-
(2012)
54th ASH Annual Meeting and Exposition
-
-
Chiappella, A.1
Franceschetti, S.2
Castellino, A.3
Carella, A.M.4
-
128
-
-
80054098574
-
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
-
Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053-4061.
-
(2011)
Blood.
, vol.118
, Issue.15
, pp. 4053-4061
-
-
Micallef, I.N.1
Maurer, M.J.2
Wiseman, G.A.3
-
129
-
-
84857522968
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
-
Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6): 631-636.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.6
, pp. 631-636
-
-
Coiffier, B.1
Pro, B.2
Prince, H.M.3
-
130
-
-
84867641179
-
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial
-
Zinzani PL, Khuageva NK, Wang H, et al. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012;5:67.
-
(2012)
J Hematol Oncol.
, vol.5
, pp. 67
-
-
Zinzani, P.L.1
Khuageva, N.K.2
Wang, H.3
|